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Abstract
Objectives: Accurate methods of estimating HIV-1 incidence are critical for monitoring the status of the epidemic and the
impact of prevention strategies. Although several laboratory-based tests have been developed strictly for this purpose,
several limitations exist and improved methods or technologies are needed. We sought to further optimize a previously
described bead-based, HIV-1-specific multiplex assay with the capability of measuring multiple immune responses for
determining recent infection.
Methods: We refined the customized HIV-1 Bio-Plex assay by determining cutoffs and mean durations of recency (MDR),
based on the reactivity to longitudinal seroconversion specimens (n = 1347) from 311 ART-naı̈ve, HIV-1-infected subjects.
False-recent rates (FRRs) were calculated for various long-term cohorts, including AIDS patients, individuals on ART, and
subtype C specimens. Incidence was estimated for each individual assay analyte from a simulated population with a known
incidence of 1%. For improved incidence estimates, multi-analyte algorithms based on combinations of 3 to 6 analytes were
evaluated and compared to the performance of each individual analyte.
Results: The MDR for the six analytes varied from 164.2 to 279.4 days, while the multi-analyte algorithm MDRs were less
variable with a minimum and maximum value of 228.4 and 277.9 days, respectively. The FRRs for the 7 multi-analyte
algorithms evaluated in this study varied from 0.3% to 3.1%, in a population of ART-naı̈ve, long-term individuals. All
algorithms yielded improved incidence estimates as compared to the individual analytes, predicting an incidence of 0.95%
to 1.02%.
Conclusions: The HIV-specific multiplex assay described here measures several distinct immune responses in a single assay,
allowing for the consideration of multi-analyte algorithms for improved HIV incidence estimates.
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Introduction
Controlling or eradicating the HIV epidemic remains a public
health priority, as well as a major challenge. The estimation of new
HIV infections in the population, or incidence, is crucial for
understanding the status of the epidemic and providing informa-
tion regarding the impact of prevention measures. In the last 15
years, several laboratory assays or tests for recent infection (TRIs)
have been developed for distinguishing recent from long-term
HIV infection, based on the reactivity to a specific biomarker [1–
11]. These TRIs rely on the principle that reactivity to a particular
biomarker, typically HIV-specific antibody levels or avidity, will
increase predictably over time post-infection. An individual is
classified as recently infected (i.e., infected within a defined mean
duration of recency (MDR)) if the biomarker value is below the
predetermined assay threshold. The BED-CEIA, which measures
the proportion of IgG antibody directed towards an immunodo-
minant gp41 oligopeptide, is the most well-known TRI and the
first commercial assay designed specifically for the purpose of
determining recent HIV infection [4,12]. The BED assay has been
employed worldwide for HIV incidence surveillance. To date, the
HIV-1 Limiting Antigen (LAg)-Avidity EIA (Sedia Biosciences
Corp., Portland, OR) is the only other TRI that has been
commercialized for HIV-1 surveillance purposes. Like the BED
assay, the LAg-Avidity EIA measures the reactivity to an antigen
representing a subtype-conserved, immunodominant region of
gp41; however, the antigen is ‘‘limited’’ on the assay plate to
exclusively allow binding of high avidity antibodies [9,10].
Recent concerns have been raised regarding the accuracy of
current TRIs based on several reports describing the overestima-
tion of HIV incidence in certain populations by the BED assay
[13–15]. HIV-1 subtype diversity in the target population likely
plays a role in the misclassification of long-term infections as recent
or false-recent rate (FRR) associated with the BED assay, given
that the MDR can vary from subtype to subtype [16].
Additionally, all serology-based TRIs are subject to some degree
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of error, as factors that disrupt the immune response to HIV, such
as progression to AIDS and antiretroviral therapy (ART), will alter
test performance; a phenomenon that has been well-documented
[1,3,4,11,17–19]. All of these cofounding variables may contribute
to inaccurate incidence estimates, which can have profound
consequences for evaluating the impact of HIV prevention or
surveillance program measures. Since these variables are present
to some degree in most populations, along with innate immune
variation, it is unlikely that an assay relying on a single biomarker
value will reliably predict recent HIV infection in all settings.
Despite the challenges associated with current TRIs, laboratory-
based assays remain attractive for incidence estimation because
they are relatively easy to perform on cross-sectional samples and
are less costly than cohort studies, which involve regular
monitoring of high-risk HIV-negative individuals in order to
identify new infections. Given these advantages, there is a pressing
need to improve the performance of current TRIs or to identify
novel biomarkers and/or technologies that compensate for
immune diversity, thereby yielding low FRRs (#2%) and
acceptable MDRs (between 4 and 12 months) [20]. In August of
2011, the WHO Working Group on HIV Incidence Assays was
convened to discuss the relevance of new and existing TRIs and to
develop guidelines for those seeking to design new assays [21].
One approach gaining consideration is the use of an algorithm
based on multiple tests and/or clinical data to improve the
accuracy of incidence estimates. Recent studies examining the
utility of an algorithm based on multiple TRIs in conjunction with
clinical data, such as CD4 counts, have shown improved specificity
as compared to each individual test [22,23]. The algorithm
approach, however, is not without its potential logistical problems,
since the requirement for multiple tests would be prohibitively
expensive and difficult to implement in certain testing settings.
Recently, we described the development of a bead-based
multiplex assay for determining recent HIV-1 infection, using
the Bio-Plex platform [24]. While most TRIs measure HIV-
specific antibody levels or avidity, the customized Bio-Plex assay
incorporates both measures against multiple analytes in a single
assay format. Preliminary analyses indicated a measurable
difference in reactivity between specimens of known recent and
long-term infection for seven different analytes. Here, we describe
the further refinement of the assay, including estimation of cutoff
values, corresponding MDRs, and FRRs for each individual
analyte in the assay. We also evaluate the utility of multi-analyte
algorithms based on different combinations of analytes for
minimizing FRRs and improving incidence estimation.
Materials and Methods
Longitudinal Seroconversion Panels and Cohorts
For estimation of cutoff values, MDR, and incidence, 1347
specimens collected from 311 ART-naı̈ve, HIV-1-infected subjects
were evaluated. Longitudinal seroconversion specimens from
subtype B HIV-infected individuals were obtained commercially
or from several prospective studies and described as follows:
12 HIV-1 seroconversion panels (n = 62) were purchased from
Zeptometrix Corp. (Buffalo, NY) and 14 panels (n = 42) were
obtained from SeraCare Life Sciences (formerly Boston Biomedica
Inc.; Milford, MA). Longitudinal specimens from 95 recent
seroconverters (n = 397) were collected as part of the Vaccine
Preparedness Study for the HIV Network for Prevention Trials
(HIVNET; ClinicalTrials.gov identifier NCT00000915), as de-
scribed in detail [24–26]. For this particular cohort, the interval of
time between the last negative and first positive antibody test
varied greatly, from 30–364 days. Specimens from 62 subjects
(n = 274) were obtained from the AIDSVAX B/B Phase III
Vaccine Trial (VAX004; ClinicalTrials.gov identifier
NCT00002441) [27]. The double-blind, randomized trial involved
the evaluation of a candidate vaccine composed of recombinant
gp120 antigens (AIDSVAX B/B; VaxGen Inc, South San
Francisco, CA). Study participants were enrolled at various sites
in North America and The Netherlands and included men who
have sex with men (MSM) and high-risk heterosexual women. To
avoid confounding variables elicited from the vaccine, only
specimens from placebo recipients that became HIV infected
during the vaccine trial were evaluated in the present study. Once
an individual became infected, samples were collected at ,1
month and 1, 2, 4, 8, 12, 16, 20, and 24 months post-diagnosis.
Longitudinal seroconversion specimens from non-B subtype
infections were obtained from two separate studies. Specimens
from 105 subjects (n = 349) with HIV-1 subtype B and E infections
were collected as part of the AIDSVAX B/E Phase III Vaccine
Trial (VAX003; ClinicalTrials.gov identifier NCT00006327),
evaluating a bivalent recombinant gp120 protein among injection
drug users (IDUs) in Bangkok, Thailand [28,29]. As described for
VAX004, only specimens from study subjects that became infected
while receiving the placebo were included in our evaluations.
Additionally, 14 seroconverters (n = 131) of subtypes G and A/G
were identified through the Recruiting Acute Cases of HIV
(REACH) study. Acute cases of HIV-1 were obtained from
screening high-risk individuals in Abuja and Jos, Nigeria. Study
designs and sample collection have been described in detail
previously [24,30].
Specimens from Long-term Infections
For estimation of false-recent rate (FRR), samples from known
long-term infected individuals (collected .365 days post-serocon-
version) were evaluated. Longitudinal specimens (n = 708) from
103 subjects were obtained from a prospective study involving
HIV-1 infected MSM diagnosed with unexplained, generalized
lymphadenopathy syndrome [31–33]. Study participants were
enrolled between 1982 and 1983 in Atlanta, Georgia and
monitored at 3- to 6-month intervals for clinical and immunolog-
ical evaluation of progression to AIDS, including CD4+ T cell
count determination. Since last negative and first positive antibody
test dates are unavailable for this cohort, samples were excluded if
the sample collection date was ,365 days from study entry or
initial sample collection. Of the 103 subjects evaluated in the
present study, 47 eventually progressed to AIDS, as determined by
CD4+ T cell count.
The impact of ART treatment and subtype diversity on FRR
was evaluated using the following cohorts: 67 subjects (n = 393
specimens) from the HIVNET cohort received ART at the time of
one or more sample collections. An estimated time from
seroconversion to ART initiation was determined based upon
the ART status of the study subject at the time of each sample
collection. A collection of subtype C specimens (n = 67) from
ART-naı̈ve long-term individuals (CHAVI001) was obtained
through the Center for HIV/AIDS Vaccine Immunology [34].
HIV-1 Multiplex Assay
The HIV-1-specific Bio-Plex assay was performed as previously
described [24] for the detection of IgG reactivity and avidity
directed against COOH microspheres (Bio-Rad Laboratories,
Hercules, CA) coupled with the following recombinant HIV-1
proteins: p66 (Protein Sciences Corp., Meriden, CT), gp120,
gp160, and gp41 (Immunodiagnostics, Inc., Woburn, MA). All
plasma/serum samples were tested in duplicate under both
treatment conditions, with and without diethylamine (DEA). A
A Multiplex Assay for HIV-1 Incidence
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normalized mean fluorescent intensity (MFI) value and avidity
index were calculated as previously described [24].
Determination of Cutoff Values
Cutoff values for recent/long-term classification were deter-
mined as described previously [24] for the following analytes:
gp120-normalized MFI value (n), gp160-n, p66-avidity index (a),
gp120-a, gp160-a, and gp41-a. Based on the large degree of
overlap in reactivity to p66-n between known recent and long-
term specimens [24], this analyte was not included in the current
study. Normalized values for gp120 and gp160 were fit to 2-
parameter nonlinear regression models [35] with random effects.
The model formula is Y = (x*A)/(B+x), where Y is analyte
response at x days since seroconversion, A is the maximum value
of the analyte response, and B is the time since seroconversion at
half maximal response. In addition to visualizing how well the
model curve approximates the true curve, goodness of fit was
assessed using residual plots and residual variance. For the
purposes of curve-fitting, time since seroconversion was defined
as the midpoint between the last negative and first positive
Western Blot result. The intervals of time between the last negative
and first positive test date did not exceed 365 days, with a
minimum of 1 day and a maximum of 364 days.
Subject-specific avidity measurements were fit to a 4-parameter
logistic (4 PL) nonlinear regression model [36], with a random
effect to account for the within-subject correlation of measure-
ments [37,38]. The 4 PL model equation is Y = D+(A2D)/(1+(x/
C) B), where Y is analyte response (avidity index) at time (x days)
since seroconversion, A is the background level (lower limit)
analyte response, D is the maximum level (upper limit) analyte
response, C is the mid-range inflection point on the curve, and B is
a slope factor or steepness of the curve. This function provides an
accurate representation of the sigmoidal relationship between the
measured response and time since seroconversion.
Selection of a cutoff value for defining recent infection was
characterized by analyte values that are as high as possible but no
greater than the model-predicted half maximal response, i.e.
analyte values at which the slope begins to decrease and analyte
values are leveling. The half maximal response or inflection point
is a well-characterized parameter of fitted regression curves, which
is reached within the initial year post-seroconversion for the Bio-
Plex analytes. Therefore, we defined a plausible cutoff value that
was between the estimated half maximal response and the lower
99% confidence limit of this estimate.
Selection of Analyte Combinations and Cutoff Criteria
To evaluate the performance of multi-analyte algorithms,
various combinations of 3–6 analytes were selected. Since
antibody avidity appears to be a robust predictor of recent
infection, 3–4 avidity measures were included in each algorithm,
with or without the least predictive analyte, p66-a. In addition to
the avidity measures, one or both of the normalized values, gp120-
n and gp160-n, were included in all but one of the algorithms. The
cutoff criteria for each algorithm, as listed in Table 1, indicate the
number of analytes, out of the total included in the algorithm, that
must cross the threshold established for each analyte (recent/long-
term cutoff for each analyte) in order to classify the individual as
having progressed from recent to long-term infection. For
example, a cutoff criterion of 3/5 indicates that a particular
individual is considered recent until 3 out of the 5 analytes in the
combination yields values above their respective cutoffs. Multiple
cutoff criteria were evaluated for each algorithm, however, only
those that provided the best incidence estimates are shown in
Table 1.
Estimation of Mean Duration of Recency (MDR)
The MDR was estimated for each individual analyte and for
each analyte combination or algorithm. Survival methods used to
estimate the MDR between time of seroconversion and time when
a selected biomarker cutoff value is reached have been described
previously [16]. Briefly, time since seroconversion was multiply
imputed 10 times using a predictive mean matching regression
method for data with monotone missing patterns [39], conditional
on its occurrence between the last negative and first positive HIV
test dates. Before application of the imputation model, linear
mixed effects regression of days since the midpoint between last
negative and first positive HIV tests was performed on analyte
measurements to estimate the increase per day (slope) and model
intercept. In addition to slope and intercept, the imputation model
included covariates for HIV subtype, time since seroconversion,
and analyte measurement value for the observation with the
closest fit to the estimated linear regression slope. We assumed the
seroconversion dates were non-missing and equal to the midpoint
of the interval for those seroconverters with intervals of #90 days
between last negative and first positive tests. For seroconverters
with at least one measurement greater than the selected cutoff
value, the estimated time when the cutoff was reached was linearly
interpolated from times at which values first reached the selected
cutoff value and the preceding longitudinal observation. Obser-
vations were right-censored at the time of the highest value for
those seroconverters who did not have a value greater than the
selected cutoff. The MDR for a predefined combination of 3–6
analytes is the estimated time between seroconversion and when
the selected cutoff value for the 2nd or 3rd, depending on the
criterion, analyte is reached.
A recently published, improved estimator for HIV incidence
introduces a timescale, T, describing the dynamic range of recency
[40]. The MDR, or average time spent alive and recently infected
at T = 1 year, is calculated using the trapezoidal rule for estimation
of area under the curve [41,42].
Estimation of False-recent Rate (FRR)
The second important parameter for estimation of HIV
incidence, the FRR, is the probability that a person infected for
longer than T will be misclassified as recently infected by having a
measurement value below the selected cutoff value for a given
analyte. FRR was calculated from specimens collected from
persons with known long-term infection (.365 days post-
seroconversion). Exact binomial confidence limits (95%) were
calculated.
Estimation of Incidence
For an overall evaluation of the analytes, singly or in
combination, the two calculated incidence parameters, MDR &
FRR, were used to calculate incidence (I) in a simulated
population using the following formula: I = (R – FRR*P)/
(N*(MDR-FRR*T)), where R is the number of recent infections,
P is the total number of prevalent infections, N is the total number
of HIV-negatives, and FRR, MDR, and T are as previously
defined. For modeling incidence estimation, data were randomly
split into two datasets. Although the collective data were obtained
from the same cohorts, one set of data was used to calculate the
MDR and FRR parameters; the other set was used for estimation
of incidence. To better reflect cross-sectional data, a bootstrap
resampling (100 replicates) of the incidence dataset was performed
such that the data were uniformly distributed with respect to time
since seroconversion within two time frames, and $ T = 1 year.
In addition, data ,T were sampled to represent 40% of the data
set. The total number of HIV-negative (N) entered into the
A Multiplex Assay for HIV-1 Incidence
PLOS ONE | www.plosone.org 3 May 2013 | Volume 8 | Issue 5 | e64201
incidence formula was fixed at a number such that the true
incidence was 1%. For example, 1825 prevalent HIV infections
were randomly selected within uniform distribution in both time
periods. Of these, 730 were recent and 1095 were long-term (40%
of all HIV infections are recent). For 1% incidence, given 730
recent infections per 73000 negative or recent, the total number of
HIV negative is 72270. In this example, R = 730, P = 1825,
N = 72270, where R and P reflect bootstrap resampling from the
actual data with constraints for their uniform distribution over
time. Relative percent difference from 1% incidence was
calculated based upon our results from the Bio-Plex analytes or
combinations of analytes.
Results
Cutoff Values and Mean Duration of Recency
Antibody binding and avidity to the analytes, gp120-n, gp160-n,
p66-a, gp120-a, gp160-a, and gp41-a, were measured on the Bio-
Plex assay for a total of 1347 specimens. For all analytes, a similar
increase in reactivity post-seroconversion was observed; however,
the range of reactivity and maximum attainable values varied from
analyte to analyte (Figure 1). Selected cutoff values for each
analyte are displayed in the graphs as solid black lines and were
chosen based on the inflection point in the curve fit. The cutoff
values for each individual analyte and combination of analytes that
were selected for further evaluation are listed in Table 1.
The MDR for the six analytes varied from 164.2 to 279.4 days
(Table 1), reflecting the differing kinetics of antibody reactivity
shown in Figure 1. The mean interval for a seroconverter to reach
the analyte-specific cutoff was shorter for the normalized values, as
compared to the avidity measures (Table 1). The median MDR for
the individual analytes was 229.4 days. Algorithm MDRs ranged
from 228.4 to 277.9 days, with a median MDR of 256.6 days.
Estimation of HIV Incidence
To evaluate the performance of the Bio-Plex assay in estimating
incidence, the FRRs of representative long-term populations were
calculated for each analyte and algorithm (Table 1). The FRR
varied considerably between the analytes, ranging from 0.3–
27.8%. The gp160 protein was associated with the lowest
misclassification rate, yielding FRRs of 0.3% and 1.1% for the
normalized values and avidity index, respectively. In contrast, p66-
a was the least specific analyte, with a FRR of 27.8%. The FRRs
for the 7 algorithms were considerably less variable, with a
minimum and maximum value of 0.3% and 3.1%, respectively.
HIV-1 incidence was calculated based on a resampled data set
with a known incidence of 1% (Table 1). All of the individual
analytes overestimated incidence, with estimates ranging from
1.07% to 1.19%. The relative difference, as compared to actual
incidence, ranged from 7.2% to 19.5%. The multi-analyte
algorithms improved incidence estimates in all cases. The
algorithm estimates ranged from 0.95% to 1.02%, with relative
differences from actual incidence ranging from -4.8% to 2.4%.
The 95% confidence intervals included the expected incidence of
1% for all but one algorithm.
False-recent Rate in Challenging Cohorts
The value of a multi-analyte algorithm compared to a single
assay measure was evaluated by comparing the FRR in cohorts
typically associated with higher misclassification rates (Table 2).
To determine the potential impact of AIDS progression on the
FRR, values were compared for a long-term MSM cohort with
specimens collected prior to and after progression to AIDS. The
FRRs were similar regardless of whether the AIDS specimens were
included in the estimates, exhibiting a minimum and maximum
value for the individual analytes of 0.7% and 28.2% with AIDS
cases and 0.6% and 27.8% for non-AIDS cases (Table 2). In both
groups, the gp160 antigen elicited the lowest FRRs (#1%). As
compared to the values for the individual analytes, the lowest FRR
of the multi-analyte algorithms dropped to 0.1% and 0.2% for the
MSM cohort with and without AIDS, respectively.
Since ART can confound serologic-based TRIs [17–19], we
evaluated long-term specimens from a longitudinal cohort with
known dates of ART initiation. For baseline comparison, we first
evaluated samples that were collected from ART-naı̈ve individuals
or at time points prior to ART initiation. In general, the HIVNET
cohort was associated with a high FRR, as all analytes and
algorithms exhibited FRRs greater than 2%. To determine the
Table 1. Characterization of the HIV-1-specific Bio-Plex.
Analyte/Algorithm Cutoff MDR FRR Incidence (95% CI) % Differenceb
gp160-a 25 235.1 1.1 1.07 (1.04, 1.10) 7.2
gp120-a 20 265.0 4.5 1.07 (1.04, 1.10) 6.6
gp41-a 35 223.6 3.4 1.11 (1.08, 1.15) 11.5
p66-a 10 279.4 27.8 1.14 (1.08, 1.20) 14.2
gp160-n 5 164.2 0.3 1.18 (1.14, 1.22) 18.1
gp120-n 7 175.9 8.4 1.19 (1.13, 1.26) 19.5
160 n, 120 n, 66a, 120a, 160a, 41a 3/6a 228.4 0.3 1.02 (1.00, 1.05) 2.4
160 n, 66a, 120a, 160a, 41a 3/5 256.6 1.1 .98 (0.95, 1.00) 22.5
120 n, 66a, 120a, 160a, 41a 3/5 264.2 2.3 .95 (0.93, 0.98) 24.8
160 n, 120n, 120a, 160a, 41a 3/5 238.6 0.3 1.02 (1.00, 1.04) 2.0
120 n, 120a, 160a, 41a 3/4 277.9 3.1 0.99 (0.96, 1.01) 21.4
160 n, 120a, 160a, 41a 3/4 265.6 1.4 1.00 (0.98, 1.03) 0.4
120a, 160a, 41a 2/3 250.3 1.4 1.02 (0.99, 1.05) 2.0
aAlgorithm cutoffs are listed as the number of analytes that must measure above each analyte-specific cutoff to be considered long-term over the total number of
analytes in the algorithm.
bRelative % difference from actual population incidence.
doi:10.1371/journal.pone.0064201.t001
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Figure 1. Longitudinal HIV-1-specific antibody responses. The normalized values (A) and avidity index (B), as measured by the Bio-Plex assay,
for longitudinal seroconverters were plotted over days since seroconversion. Gray diamonds indicate individual data points and solid black circles
represent the curve fit for each graph. Dashed red lines represent the half maximal response of the curve and lower 99.9% confidence limits of the
estimate, while the solid black line represents the selected cutoff.
doi:10.1371/journal.pone.0064201.g001
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impact of ART treatment on the performance of the multi-analyte
assay, the ART-treated specimens were designated as ‘‘early’’ or
‘‘late’’, based on whether ART was initiated within 365 days post-
seroconversion or after. Early ART initiation was associated with a
higher FRR, as compared to the ART-negative population
(Table 2). However, when ART was initiated greater than a year
post-seroconversion, the FRRs for most of the individual analytes
and algorithms were similar to the ART-negative group. In the
absence of ART, four of the algorithms exhibited lower FRRs as
compared to the best performing individual analyte, gp160-n. In
general, the FRRs were lower for the algorithms as compared to
the individual analytes; however, the added advantage of multiple
analytes was less powerful when ART was initiated within the first
year post-seroconversion. With the exception of the early ART
treatment group, the six-analyte algorithm provided the lowest
FRR of all algorithms evaluated in this study (Table 2).
Lastly, the performance of the Bio-Plex assay on one non-B
subtype specimen set was assessed using a cohort of subtype C
specimens from ART-naı̈ve long-term individuals. Gp160-a,
gp120-a, and all seven of the algorithms exhibited a FRR of 0%
(Table 3).
Discussion
In this study, we evaluated the utility of multi-analyte algorithms
for improved HIV incidence estimates using the Bio-Plex assay.
Although the HIV-specific antibody responses displayed similar
patterns of reactivity, each analyte exhibited a unique rate of
increase and scale of reactivity. It was, therefore, necessary to
consider each analyte as a separate test, with a distinct cutoff and
MDR estimate. Our preliminary analyses indicated that selecting
analyte cutoffs based on the natural inflection point in the curve of
longitudinal reactivity allowed for the greatest distinction in
reactivity between recent and long-term specimens with the Bio-
Plex assay, as opposed to selecting the cutoff based on a set MDR
(e.g., 180 or 365 days; data not shown). When relying on a single-
assay measure, a certain percentage of the population may never
reach the threshold for a particular biomarker due to innate
differences in the immune response from individual to individual.
Therefore, cutoff criteria for the analyte combinations or
algorithms were selected to allow for some degree of immune
variation. Instead of basing the classification of recent infection on
the full agreement of each test or analyte result, a pre-determined
number of analytes less than the total included in the algorithm
needed to meet the criteria or score above the threshold to
consider an individual long-term. Based on the algorithm cutoff
criteria described here, one or more analytes can ‘‘fail’’ or never
Table 2. Impact of disease progression and antiretroviral use on false-recent rates.
FRR (95% CI)





Analyte/Algorithm (n = 540) (n = 708) (n = 138) (n = 299) (n = 94)
gp160-a 0.7 (0.2, 1.9) 0.7 (0.2, 1.6) 10.9 (6.2, 17.3) 16.4 (12.4, 21.1) 3.2 (0.7, 9.0)
gp120-a 2.6 (1.4, 4.3) 3.2 (2.1, 4.8) 11.6 (6.8, 18.1) 7.0 (4.4, 10.5) 13.8 (7.6, 22.5)
gp41-a 2.8 (1.6, 4.5) 2.4 (1.4, 3.8) 9.4 (5.1, 15.6) 24.7 (20.0, 30.0) 11.7 (6.0, 20.0)
p66-a 27.8 (24.0, 31.8) 28.2 (25.0, 31.7) 27.5 (20.3, 35.8) 39.8 (34.2, 45.6) 44.7 (34.4, 55.3)
gp160-n 0.6 (0.1, 1.6) 1.0 (0.4, 2.0) 7.2 (3.5, 12.9) 26.1 (21.2, 31.5) 6.4 (2.4, 13.4)
gp120-n 3.5 (2.1, 5.4) 7.5 (5.7, 9.7) 8.7 (4.6, 14.7) 36.1 (30.7, 41.9) 28.7 (19.9, 39.0)
160n, 120n, 66a, 120a, 160a, 41a 0.2 (0.0, 1.0) 0.1 (0.0, 0.8) 4.3 (1.6, 9.2) 17.7 (13.6, 22.5) 4.3 (1.2, 10.5)
160n, 66a, 120a, 160a, 41a 0.9 (0.3, 2.2) 0.7 (0.2, 1.6) 5.1 (2.1, 10.2) 18.1 (13.9, 22.9) 4.3 (1.2, 10.5)
120n, 66a, 120a, 160a, 41a 1.1 (0.4, 2.4) 1.3 (0.6, 2.4) 5.1 (2.1, 10.2) 18.4 (14.2, 23.3) 9.6 (4.5, 17.4)
160n, 120n, 120a, 160a, 41a 0.4 (0.0, 1.3) 0.6 (0.2, 1.4) 7.2 (3.5, 12.9) 19.7 (15.4, 24.7) 4.3 (1.2, 10.5)
120n, 120a, 160a, 41a 1.3 (0.5, 2.7) 2.0 (1.1, 3.3) 9.4 (5.1, 15.6) 21.4 (16.9, 26.5) 12.8 (6.8, 21.2)
160n, 120a, 160a, 41a 0.9 (0.3, 2.2) 1.1 (0.5, 2.2) 9.4 (5.1, 15.6) 20.1 (15.7, 25.1) 5.3 (1.8, 12.0)
120a, 160a, 41a 0.9 (0.3, 2.2) 0.8 (0.3, 1.8) 6.5 (3.0, 12.0) 14.0 (10.3, 18.5) 4.3 (1.2, 10.5)
aIncludes entire MSM cohort.
doi:10.1371/journal.pone.0064201.t002
Table 3. Bio-Plex assay performance on subtype C
specimens.
FRR (95% CI)
Analyte/Algorithm CHAVI (n = 67)
gp160-a 0.0 (0.0, 5.4)
gp120-a 0.0 (0.0, 5.4)
gp41-a 1.5 (0.0, 8.0)
p66-a 4.5 (0.9, 12.5)
gp160-n 1.5 (0.0, 8.0)
gp120-n 1.5 (0.0, 8.0)
160n, 120n, 66a, 120a, 160a, 41a 0.0 (0.0, 5.4)
160n, 66a, 120a, 160a, 41a 0.0 (0.0, 5.4)
120n, 66a, 120a, 160a, 41a 0.0 (0.0, 5.4)
160n, 120n, 120a, 160a, 41a 0.0 (0.0, 5.4)
120n, 120a, 160a, 41a 0.0 (0.0, 5.4)
160n, 120a, 160a, 41a 0.0 (0.0, 5.4)
120a, 160a, 41a 0.0 (0.0, 5.4)
doi:10.1371/journal.pone.0064201.t003
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reach the analyte cutoff, without affecting the final assay
determination for an individual infected for a time period longer
than the MDR. A minimum of three analytes were included in
each algorithm to maintain the described cutoff criteria.
Since it was unknown whether an algorithm based on TRIs or
assay measures would improve HIV incidence estimates, we
evaluated the performance of each individual analyte in compar-
ison to various multi-analyte algorithms. One of the biggest
challenges in validating candidate TRIs is the difficulty in
obtaining well-characterized cohorts with known incidence rates.
For proof-of-concept purposes, we used resampled data to
generate a simulated ART-naı̈ve cohort with a known incidence
of 1%. A limitation of the current study is that the simulated
population for incidence evaluation was derived from the same
cohorts used to calculate the MDRs and FRRs for the individual
analytes and algorithms. Even though all of the algorithms,
regardless of whether 3, 4, 5, or 6 analytes were included, yielded
improved incidence estimates as compared to the individual
analytes, it is essential to validate algorithm performance in diverse
populations, especially those associated with high FRRs. Reasons
for high FRRs in specific populations may be numerous, so we
assessed two confounding factors that are typically associated with
a reduction in the antibody response to HIV, progression to AIDS
and ART. Individuals that progress to AIDS often exhibit a
decline in HIV-specific antibody levels, leading to a higher
likelihood of misclassification by some TRIs [1,3,4,11]. In
contrast, we observed minimal to no impact on antibody reactivity
when specimens from AIDS cases were included in the analyses,
which is likely due to the high sensitivity of the Bio-Plex assay
format. ART use is also a well-documented challenge for most
antibody-based assays, given that reduction in viral loads leads to
reduced antigenic stimulation necessary for antibody production
and maturation. In this study, we observed a notable difference in
assay performance depending on the timing of ART initiation
post-seroconversion, which indicated that a sustainable HIV-
specific antibody response is dependent upon adequate virus
replication within the first year post-infection.
In general, one or more of the analyte algorithms exhibited
lower FRRs as compared to the individual analytes; however, the
added advantage of multiple analytes was less convincing for the
early ART initiation group which had unusually high FRRs. For
the early ART specimens, one individual analyte (gp120-a)
exhibited a FRR lower than all of the algorithms, including non-
overlapping 95% confidence limits. It is not known whether this
finding is meaningful or the result of small sample sizes or other
cohort-specific variables. Although the impact of early ART on
assay performance is clear, the cohort used in this study was
associated with a high FRR in general, as also demonstrated by the
BED assay (FRR = 10%; data not shown). It is likely that the high
FRR associated with this particular cohort is due to relatively large
intervals of time between the last negative and first positive
antibody test dates for the majority of the study participants,
leading to uncertainty around the estimated seroconversion dates.
Duration of time on ART may also correlate with an increase in
misclassification; however, this variable was not addressed in the
present study. Additionally, viral load data were not available for
this cohort, so the direct effect of ART-induced virus suppression
on assay performance could not be measured. Further investiga-
tion, using well-characterized longitudinal specimens with rela-
tively short sample collection intervals, is needed to fully assess the
potential benefit of a multi-analyte algorithm in populations with
high ART use. Furthermore, ongoing research involves the
evaluation of additional biomarkers that may not be affected by
declining virus levels. One such candidate is anti-p24 IgG3, which
has been shown to peak during early infection, but unlike IgG1
levels, declines to low or undetectable levels shortly thereafter [43].
Preliminary studies in our laboratory have indicated that peak
IgG3 levels occur prior to the initiation of ART in most individuals
(data not shown). Moreover, the Bio-Plex format is not limited to
the detection of antibody biomarkers, such that alternative
immune activation biomarkers can be assessed.
The assay performance described here is highly encouraging;
however, all new incidence assays or technologies must be
carefully validated prior to field implementation. The current
assay format will be further assessed to determine inter-lab
variation and performance on diverse HIV-1 subtypes. Since the
Bio-Plex assay was designed with subtype B antigens, care must be
taken to avoid generalizing about assay performance with diverse
subtypes based on the reactivity of subtype B samples. We
observed a low or zero FRR with subtype C samples from long-
term individuals, however, the cohort size was relatively small and
additional subtypes were not evaluated due to lack of availability.
To address potential discrepancies in the reaction kinetics of non-B
subtype specimens, we plan to evaluate subtype conserved peptides
and recombinant proteins, in addition to the current analytes.
One challenge that we expect to face in validating the multiplex
assay is identifying criteria for selecting the best algorithm or
algorithms for use in diverse populations. Although FRR is a
valuable measurement for test evaluation, it does not necessarily
predict the analytes or algorithms that provide the most accurate
incidence estimates. However, since FRR is a key component of
the formula used to calculate HIV incidence, it is desirable to
identify a combination of analytes that produces the lowest or
negligible FRR, while maintaining a sufficient MDR for feasible
incidence calculations. Further testing is also needed to determine
the necessity of each recombinant protein included in the current
format of the assay. Another potential challenge of the current
assay format is the need for dedicated equipment that may be
difficult to acquire in certain testing settings. Future plans include
the identification and evaluation of portable versions of the Bio-
Plex format and/or alternative, low-tech platforms with multi-
plexing capability.
The results described here demonstrate the advantage of a
multiplex system that enables measurement of multiple analytes
for improved cross-sectional HIV-1 incidence estimates. We
demonstrate that a multi-analyte algorithm based on three or
more assay measures provides lower FRRs and improved
incidence estimates. We emphasize that all cutoffs and MDRs
were estimated for proof-of-concept evaluation only and may
change after further refinement of the assay.
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